SUMMARY
We have hypothesized that in aplastic anemia (AA) the presence of antigen-specific T-cells is reflected by their contribution to the expansion of a particular variable beta chain (V ) subfamily and also by clonal CDR3 skewing. To determine the role of disease-specific "signature" T-cell clones in AA, we studied preferential Vusage by flow cytometry and analyzed V -CDR3 regions for the presence of oligoclonality. We first established the contribution of each V family to the total CD4+ and CD8+ lymphocyte pool; in AA and PNH, a seemingly random over-representation of different V families was observed. On average, we found expansion in 3 (out of 22 examined) V families per patient. When the contribution of individual V families to the effector pool was examined, more striking V -skewing was found. V -CDR3 size distribution was analyzed for the expanded V families in isolated CD4+ and CD8+ populations; under-represented V families displayed more pronounced CDR3 skewing. Expanded CD4+V subfamilies showed mostly a polyclonal CDR3 size distribution with only 38% of skewing in expanded V families. In contrast, within over-represented CD8+V types, marked CDR3 skewing (82%) was seen, consistent with non-random expansion of specific CD8+ T-cell clones. No preferential expansion of particular V families was observed, in relation with HLA-type. In patients examined before and after immunosuppressive therapy, an abnormal V -distribution pattern was retained, but the degree of expansion of individual V was lower. As V -skewing may correlate with relative V size, oligoclonality in combination with numerical V expansion can be applied to recognition of disease-specific TCR.
only.
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INTRODUCTION
Historically, the unexpected improvement of hematopoietic function in some aplastic anemia (AA) patients failing engraftment after bone marrow transplantation 1 led to the systematic application of immunosuppressive therapies, with the majority of the patients now showing hematologic recovery without transplantation. [2] [3] [4] Many laboratory data has been accumulated to support an immunologic mechanism in idiopathic AA. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Recently, molecular techniques have been applied in the study of normal and pathologic immune responses. These methods allow analysis of the T-cell repertoire using polymorphism within the complementarity determining region 3 (CDR3) of the beta variable (V ) chain of the T cell receptor (TCR). [16] [17] [18] Such an "immunoscope" approach provides a more direct view of the pattern of the T cell response and has been utilized to study autoimmune diseases including multiple sclerosis, 19 rheumatoid arthritis, 20-21 systemic lupus erythematosus, 22 type 1 diabetes mellitus, 23 thyroiditis, 24 primary biliary cirrhosis, 25 psoriasis, 26 and graft-versus-host-disease (GVHD).
27-30
Consequently, similar studies have been performed in AA. [31] [32] [33] Although specific V patterns common to all the patients could not be identified due to the HLA heterogeneity, oligoclonality in the TCR V CDR3 size distribution pattern was documented for certain V families in many AA patients. Abnormal TCR V repertoires were also found in other related bone marrow failure syndromes such as myelodysplastic syndromes (MDS) 34 and paroxysmal nocturnal hemoglobinuria (PNH), 35 suggesting a common immune-mediated pathophysiology. Nonrandom skewing in a large proportion of V families CDR3 size spectrum has suggested that different antigens may drive the immune process in individual patients. 33 We have reported that it is possible to to identify and characterize dominant T-cell clonotypes that likely represent responses to disease-specific antigens. 36 However, these initial studies also demonstrated that, given the HLA diversity and number of V families potentially involved, a broad scale analysis of multiple clonotypes in many patients is not practicable using cloning approaches and has prompted us to search for other ways of analyzing the complex nature of changes in the T-cell repertoire in AA.
Our strategy was designed for systematic detection of disease-specific "signature" T-cell clones based on several assumptions, each supported by experimental evidence in human and animal models. We hypothesized that limiting the immunoscope approach to abnormally expanded V families could provide a more specific method to identify pathologic clonotypes, eliminating the bias of skewing due to numerical contraction of the Tcell pool. Using this strategy we first identified overexpanded V families by systematic application of flow cytometry (V skewing), established oligoclonality of expanded V families using molecular techniques and, subsequently, characterized the specific predominant CDR3 clonotypic (CDR3 skewing) sequences for both CD4+ and CD8+ lymphocyte subsets. Selection of disease specific clonotypes may be useful in the analysis of antigens driving immune process in AA and be applied to classify distinct forms of AA and to monitor the 
PATIENTS AND METHODS

Patients and controls.
We studied samples obtained from 23 subjects with AA and 10 patients with PNH or the AA/PNH syndrome. In 12 cases, serial samples were examined before and after immunosuppressive therapy. Initial samples were peripheral blood (PB) obtained at the time presentation of the disease, before any treatment (except for transfusional support). Informed consent for venipuncture was obtained according to protocols approved by the Institutional Review Board of the National Heart, Lung and Blood Institute (Bethesda, MD). The diagnosis of AA was by bone marrow (BM) biopsy and PB cell counts according to the International Study of Aplastic Anemia and Agranulocytosis; 37 severity was classified by the criteria by Camitta et al. 38 For the diagnosis of severe AA (sAA), in addition to hypocellular BM without evidence of karyotypic abnormalities or morphologic dysplasia, patients had to fulfill 2 out of 3 PB criteria: absolute neutrophil count (ANC) <500/uL, absolute reticulocyte count (ARC) of <60,000/uL and platelet count of <20,000/uL of blood. Clinical characteristics of the patients studied are summarized in Table 1 . Patients were sub-grouped according to the presence of commonly encountered HLA alleles such as HLA-A2 (HLA-A*02) and HLA-DR2 (HLA-DRB1*15).
Immunosuppressive therapy consisted of a combination of anti-thymocyte globulin, cyclosporine A, and mycopholate mofetil. All patients received a course of prednisone during and after ATG. Patients were classified as responders when they no longer fulfilled the severity criteria and became transfusion-independent according to previously published criteria. 37 The presence of a PNH clone was determined by flow cytometry: the test was considered positive when >1% of glycosyl-phosphatidylinositol-anchored protein-(GPI-AP)-deficient neutrophils in blood were found as defined by negativity for surface staining for CD66b and CD16 in a distinctive population of CD15+ cells. For the purpose of this study, patients with the presence of PNH clone and otherwise fulfilling criteria of AA were classified as having AA/PNH. 39 Nine healthy subjects served as normal controls for flow cytometry experiments. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 7 intensity of each band was depicted as a peak. CDR3 size patterns that failed to exhibit a well-shaped distribution due to the appearance of prominent peaks, with or without a reduced peak number (<5 peaks), were judged as abnormal. The analysis was performed by three different investigators in blinded fashion, and in a few cases, where inconsistent results were obtained, the decision as to whether the pattern was skewed or abnormal was based on the agreement of 2 out of 3 investigators.
V cytometry (V skewing
Statistical analysis. Student's t-test was used to compare the number of overexpressed (> 2 standard deviation (SD) of normal control pool) V subfamilies in AA and PNH patients and healthy controls; paired t-test was used, in normal subjects, to compare percentage contributions of each V -class in total lymphocytes versus effector subsets. Chi-square was used to determine if specific V subfamilies were non randomly overrepresented. Overrepresentation of specific V -subfamilies was tested by 2 -test. 2 -test was also used to compare the frequency of an abnormal CDR3 size profile in overexpressed V subfamilies in CD4+ and CD8+
subsets, and in each V subfamily. All statistical analyses were performed using Statistica 5.0 software (Statsoft Inc., Cary, NC).
RESULTS
Flow cytometric analysis of V usage.
We planned experiments on the premise that either pronounced monoclonal expansion of an individual clone or superantigen-stimulation could lead to an increased contribution of a given V family (V skewing) to the whole T-cell repertoire. Therefore, we analyzed preferential usage of 22 different V subfamilies by CD4+ and CD8+ cells using flow cytometry. In addition, 9 age-matched healthy individuals established control values. All 22 V subfamilies were present in PB lymphocytes, each accounting for 0.5% to 9% of total / T-cells; variability in the percentage representation of each V family among controls was low. To obtain a normal V representation spectrum for CD4+ and CD8+ cells, results from all controls were averaged and ordered according to their contribution to the T-cell repertoire (Fig. 1) .
Subsequently, we analyzed 23 AA and 10 PNH patients: for comparison purposes, values > mean + 2 x SD of controls were considered abnormal. In AA, of a total of 22 V families, on average we found expansion in 3±2 and 2±2 V families in CD4+ and CD8+ subsets, respectively (p=0.029 and p=0.023). Similar results (3±2 for CD4+ and 3±1 for CD8+ lymphocytes; p=0.019 and p<0.001) were obtained in PNH ( Figs. 1 and 2) . Most of AA patients had received transfusion at the time of the blood sampling: out of 23 AA patients, 5 were analyzed before any transfusions were given. In addition, there was 1 PNH who did not receive any transfusions. These patients showed V oligoclonality pattern similar to those who received transfusion support, with no differences with regard to the degree or extend of V family expansions (p>0.05). No correlation was found between the numbers of expanded V families per patient (degree of V skewing) and clinical parameters such as absolute neutrophil count (ANC), reticulocyte and platelet counts at presentation ( Table 1 ). The frequency of skewing of a particular family was not homogeneous (p<0.001, 2-test); in AA, some V subfamilies appeared to be more frequently over-utilized (Fig. 3) . However, no consistent over-representation of specific V subfamilies was found when patients were grouped by HLA-A or B (analyzing CD8+ subset, p>0.05) and DR or DP phenotype (for CD4+ subset, p>0.05; 2-test).
Preferential V usage by effector CD4+ and CD8+ T-cell subpopulations. According to our initial hypothesis that effector lymphocyte subsets was more likely to contain specific V families involved in the pathologic process, we had determined the V spectrum of effector T-cells. CD28 down-modulation was used as a marker of the effector phenotype (CD4+CD28dim and CD8+CD28dim). In controls, effector cells showed deviations from the usual distribution of total CD4+ or CD8+ cells. For example, within CD4+ cells, V 1, 2, 5.1 and 16 were under-represented (p<0.05, t-test), while V 14 was expanded. In CD8+ cells, V 5.2, 6.7, 9, 13.1, 13.6 and 17 were all under-utilized in the effector pool as compared to total CD8+ T-cells. In patients, the average number of over-represented V subfamilies constituting the effector pool did not differ when compared to total CD4+ and CD8+ lymphocytes (on average, about 3 of 22 V families studied were over-represented).
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However, certain V families showed a higher degree of the expansion within effector T-cells as compared to total lymphocyte pool; in some patients, 1 or 2 V individual subfamilies represented over 50% of the total effector T-cells (Fig. 1) . Again, no consistent expansion of individual V families was found among clinically similar patients and there was no correlation with HLA class-I and class-II type (Fig. 3) .
CDR3 size distribution analysis of overrepresented V subfamilies. From the flow cytometry data, all V families overexpressed in the CD28dim compartment (effector pool) were selected as likely to represent oligo-or monoclonal expansion of disease-specific CD4+ or CD8+ T-cells. For these V families, size distribution analysis of their CDR3, amplified by PCR, was performed. For that purpose, isolated CD4+ and CD8+ cell populations were used for the amplification with specific V primer pairs.
29 Surprisingly, we found that most (72%, 35 of a total of 57 expanded V -families {in 20 patients}) of the expanded CD4+ V subfamilies showed a Gaussian-like distribution (Fig. 4) , indicating a normal polyclonal expansion within these families. In contrast, almost all (82%, 38 out of 44) V subfamilies overutilized by CD8+ cells demonstrated a skewed profile, with oligoclonal and often monoclonal patterns (Fig. 4) . The difference in the degree of V skewing between CD4+
and CD8+ expanded V families was highly (p<0.001, 2-test) In addition, for CD4+ cells, skewing was observed Clinical response and V usage after immunosuppressive treatment. Twelve of the 23 AA patients were analyzed prior to immunosuppression and 3 to 6 months after treatment. While we expected normalization of the V family and CDR3 skewing patterns seen at initial presentation, no major changes in the number of expanded V classes were found after therapy. However, numerically, over-represention of the V subfamilies was less pronounced in most of the cases, although their percentages remained >2 SD of controls regardless of clinical response (Table 1) . When parametric analysis was used to summarize the results obtained in 12 patients studied, some V families showed lower percentages after therapy (t-test, p<0.05): for total CD4+ lymphocytes, V 5.2, 6.7, 11, 14, 18 and 21.3 decreased while for CD8+ T-cells, V 5.2, 14 and 18 were lower and V 1 was higher.
When the effector pool was analyzed, CD4+V 9 T-cell showed a higher contribution to the total / T-cell pool than was observed before therapy, while CD4+V 11+, CD8+V 11+ and CD8+V 14+ lymphocytes contracted.
DISCUSSION
In AA, the evidence of an autoimmune pathophysiology is mostly indirect, as the offending antigens have not been identified. Demonstration of oligoclonal T-cell responses may serve as a surrogate for the recognition of the antigens which drive the immune process.
40-41 Our strategy of characterization of clones responsible for immune-mediated damage to hematopoietic tissue included a combination of two different concepts: that immunodominant antigens (determining disease) will produce both qualitative (CDR3 skewing pattern) and quantitative (expansion of V class) changes in each TCR V family.
Due to the wide spectrum of antigens encountered by the immune system under physiologic conditions, the normal TCR V repertoire would be expected to be similar among healthy individuals, but it is possible that the diversity of HLA-backgrounds could result in a variably distributed V spectrum. We found that the contribution of each specific V class to the total + lymphocyte pool showed little variability. These results were comparable to data published by others. 42 Therefore, it is likely that the similar utilization of individual V chains among healthy controls may reflect preferential molecular rearrangements of particular variable segments 43 rather then response to ubiquitous but different antigens.
44-45
In healthy donors, bone marrow T-cells are likely representative of preferential homing processes rather than peripheral mechanism of selection and expansion. In previous studies, no differences in the V skewing were demonstrated when simultaneously blood and bone marrow was analyzed. 35 Utilization of marrow introduces an artefact related to the various content of peripheral blood contamination and low cellularity of marrow specimens. To avoid this problem we decided to base our studies on peripheral blood. While this approach may be less sensitive, it allows in the future, a more systematic and frequent analysis and better correlation with clinical parameters. In addition, V families and clonotypes identified in blood can be selectively applied to the analysis of marrow.
When V usage was studied in 33 AA and PNH patients, marked differences in the contribution of individual V families to the T-cell pool were measured by flow cytometry; in particular, most of the patients showed overexpansion of specific V families. This effect was unlikely due to the presence of a superantigen but rather suggestive of antigen-driven clonal responses. The differences from the normal V -repertoire were even more pronounced when the effector lymphocyte pool was studied, as effector T-cell subsets are more likely to include the disease-specific, antigen-primed T-cells. In our study, over-represented V families were found in both CD4+ and CD8+ effector lymphocytes and are compatible with specific T-cell responses. However, commonly expanded specific V classes were not found even if patients were grouped according to their HLAtyping.
Previous studies included CDR3 analysis performed using total T-cell populations. [31] [32] [33] However, analysis only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From of VB in CD4+ and CD8+ cells is more rational because CDR3 spectra of cytotoxic (CTL) and helper T-cells would have different HLA-restrictions and might overlap when analyzed in combination. We used expansion of specific V families to limit the search for the disease-specific clones distinguished by unique CDR3 nucleotide sequences. Consequently, we have analyzed CDR3 size distribution only within the numerically over-represented V families. We found that while the expansion of certain V families was associated with oligoclonality in the CD8+ subset, V expansions in CD4+ cells were more likely to be polyclonal. These results indicate that our method is more useful to recognize disease-specific cells within the CD8+ subset as CTL contain distinct T-cell clones. By comparison, CD4+ responses may be more complex and V CDR3 size analysis may not be helpful. For example, a quantitatively weak clonal CD4 expansions may serve to amplify the final CD8 effector pathway.
Our previous studies have shown that V CDR3 skewing can also be related to the contraction in the total T-cell compartment and a reflection of clonal sparing. 33 Many different factors may contribute to TCR repertoire impairment in AA; first, cytopenia may also involve lymphocytes, with reduction of specific T-cell subsets.
Second, the underlying immunologic disorder itself may be responsible for the contraction of T-cell repertoire.
Third, contraction can result from immunosuppressive therapy 33 or after BMT. 47 Instead, we observed that within the CD4 T-cell population, the size of a particular V family appears to correlate with the likelihood of skewing.
At least in theory, our findings may be due to transfusions or infections, and it is not possible to rigorously exclude this possibility. However, in our previous studies, we did not observe increased CDR3 skewing in polytransfused patients, and none of our current patients was clinically infected at the time of blood sampling.
Moreover, in this study few patients were analyzed before any transfusion, and they showed no differences with regard to the degree or extend of V expansion compared to those patients who received transfusion support.
Lack of direct clinical correlations (such as total normalization of V repertoire for patients in remission) may be due to persistence of the antigenic drive or to lack in the selectivity of our current immunosuppressive regimens, allowing T-cell regeneration according to the original V class distribution. Instead, major expansions usually are reduced after ATG therapy, but do not disappear, consistent with the high relapse rate. Eradication of pathological only.
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clones may be difficult, as clinically confirmed by the high incidence of relapse. However, due to the short follow up, we have not yet observed relapses in the group of AA patients who responded to immunosuppression, and comparisons of V spectrum between the time of relapse and initial presentation were not yet available.
In sum, identification of the disease-specific clonotypes can be followed by their characterization on molecular level. Ultimately, our approach will serve the goal of recognition of specific clonotypic sequences by analogy to autoantibody detection, and they should serve as surrogate molecular markers for specific etiologies or pathophysiologic pathways in autoimmune diseases. 
